Clinical trials: Side Effects
Adverse Drug Event, Drug Drug Interaction
Implementation of a Pharmacist-led Pharmacogenomic Clinical Service
Tabula Rasa HealthCare (TRHC), doing business as CareKinesis, is the first national pharmacy that provides science-based medication risk identification and mitigation technologies and services.
- Conditions
- Adverse Drug Event, Drug Drug Interaction, Pharmacogenomics, Elderly
- Trial name
- NCT04984538
- Testing
- Pharmacogenomic Testing
- Where
- United States
- Sponsor
- Tabula Rasa HealthCare
Palmar-Plantar Erythrodysesthesia Syndrome
Safety and Efficacy Placebo Controlled Study of ATH008 Cream in PPES Patients Secondary to Capecitabine
The aim of this study is to evaluate the safety and efficacy of ATH008 cream in patients with Palmar-Plantar Erythrodysesthesia Syndrome (PPES) secondary to capecitabine therapy.
- Trial name
- NCT01316406
- Testing
- ATH008
- Where
- 26 sites in Belgium, Germany and 2 more
- Volunteers
- 122 people
- Sponsor
- Advancell - Advanced In Vitro Cell Technologies, S.A.
Acne, Acne Scars
Restylane Silk Acne Scar Efficacy Evaluation Study
Randomized, double-blind, placebo-controlled, research pilot study. 30 subjects aged 22-55 years old of all skin types will be asked to sign an informed consent form prior to any study procedures.
- Conditions
- Acne, Acne Scars, AdverseEvent
- Trial name
- NCT02955381
- Testing
- Restylane Silk, 1.0 ml, Saline, 1.0 ml
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Schweiger Dermatology, PLLC
Acute Myocardial Infarction, Coronary Syndrome
Antiplatelet Therapy Following Stent Implantation
Coronary artery stents, particularly drug-eluting stents (DES), are used in the majority of patients who undergo percutaneous coronary intervention (PCI) to improve symptoms in patients with obstructive coronary artery disease.
- Conditions
- Acute Myocardial Infarction, Coronary Syndrome, Angina, Unstable
- Trial name
- Anti-Clot (NCT02051361)
- Where
- Greece
- Volunteers
- 900 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to assess how well ABBV-453 works adult participants with relapsed/refractory (R/R) untreated CLL/small lymphocytic…
- Trial name
- 453 Ph1 CLL (NCT06291220)
- Testing
- Obinutuzumab, ABBV-453
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 4 people
- Sponsor
- AbbVie
Obesity (Disorder), GLP-1 Receptor Agonist Treatment
Probiotics in Obese Patients Treated With Semaglutide
This randomized, double-blind, placebo-controlled trial evaluated the effects of a four-strain probiotic formulation in adults with obesity receiving semaglutide.
- Conditions
- Obesity (Disorder), GLP-1 Receptor Agonist Treatment, Probiotic Intervention, Diabetes Mellitus Type 2
- Trial name
- ProSem (NCT07847593)
- Testing
- Four-strain probiotic formulation
- Where
- 3 sites in Poland
- Volunteers
- 102 people
- Sponsor
- Nordic Biotic Sp. z o.o.
Health, Subjective, Inflammatory Response
Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults
The goal of this observational study is to provide exploratory research into the in vivo physiological and psychological effects, if any, of cannabigerol (CBG) in healthy human adults age 21 or over.
- Conditions
- Health, Subjective, Inflammatory Response, Adverse Effect, Side Effect
- Trial name
- NCT05743985
- Testing
- Cannabigerol
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Formula30A LLC
COVID-19, Vaccine Adverse Reaction
National Vaccine Adverse Event Reporting Survey and Etiology
If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use
- Trial name
- NVAERS (NCT05095844)
- Testing
- vaccinated
- Where
- United States
- Volunteers
- 100,000 people
- Sponsor
- Neuroganics LLC
Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use
Food and Insulin Effect on QT/QTC Interval of ECG
Moxifloxacin is routinely used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. It has been shown that a meal shortens the QT interval, which may affect pharmacokinetics (PK) and/or…
- Conditions
- Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use, C-Peptide Effects on the QT/QTc Interval, Moxifloxacin ECG Profile in Fed and Fasted State
- Trial name
- C11035 (NCT01642485)
- Testing
- Moxifloxacin 400 mg fasted, FDA breakfast, Continental breakfast
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Richmond Pharmacology Limited
Type 2 Diabetes, Metabolic Syndrome
Clinical Study on the Effect of a Synbiotic on Body Fat Mass
In this trial the effect of a synbiotic consisting of the three different strains of Lactobacillus fermentum and acacia gum (gum arabic) on body fat mass, body weight, long-term glycemia, insulin resistance and other risk factors…
- Conditions
- Type 2 Diabetes, Metabolic Syndrome, Obesity, Abdominal, Obesity, Visceral
- Trial name
- NCT04754464
- Testing
- synbiotic, microcrystalline cellulose
- Where
- 2 sites in Austria, Germany
- Volunteers
- 120 people
- Sponsor
- Slimbiotics GmbH
Age-related Macular Degeneration (AMD)
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
This was the cross-sectional study to assess the period prevalence of IOI in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period in 2019.
- Trial name
- NCT05146687
- Testing
- Aflibercept, Ranibizumab, Bevacizumab
- Where
- United States
- Volunteers
- 369,600 people
- Sponsor
- Novartis Pharmaceuticals
Safety of the CytaCoat Foley Catheter, Performance of the CytaCoat Foley Catheter
Assessing Safety and Performance of the Novel CytaCoat Foley Catheter
This study is a prospective, single-center, single-blind, randomized, parallel assignment, controlled study to evaluate the safety and performance of the novel CytaCoat Foley catheter when compared to a Sterimed uncoated Foley…
- Trial name
- CYTA-FOL-2 (NCT07070921)
- Testing
- Foley catheter
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- CytaCoat AB
Polymyalgia Rheumatica
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154
Polymyalgia rheumatica (PMR) is an inflammatory disease causing shoulder, hip, and neck pain and stiffness, in adults aged 50 years or older.
- Trial name
- AIM-PMR (NCT04972968)
- Testing
- ABBV-154, Glucocorticoid
- Where
- 117 sites in United States, Australia and 13 more
- Volunteers
- 181 people
- Sponsor
- AbbVie
Multiple Myeloma
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage (%) of all cancers and for 10% of all hematologic malignancies.
- Trial name
- NCT03525678
- Testing
- Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 221 people
- Sponsor
- GlaxoSmithKline
Herpes Zoster, Neuralgia
NGX-4010 for the Treatment of Postherpetic Neuralgia
The purpose of the study is determine if an investigational drug, NGX-4010 (high-concentration capsaicin dermal patches) is effective in treating pain associated with post-herpetic neuralgia (PHN).
- Conditions
- Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases
- Trial name
- NCT00061776
- Testing
- Capsaicin Dermal Patch
- Where
- 28 sites in United States
- Volunteers
- 300 people
- Sponsor
- NeurogesX
Psoriasis
Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting
Study is not recruiting and using secondary data sources only
- Trial name
- NCT04799990
- Testing
- Risankizumab, Comparator 1, Comparator 2
- Sponsor
- AbbVie
Tolerance, Side Effect
The Efficacy and Tolerability of Acarbose in Healthy Individuals
A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.
- Conditions
- Tolerance, Side Effect, Glucose Response
- Trial name
- NCT05542849
- Testing
- Acarbose Tablets 50mg
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AgelessRx
Parkinson Disease, Dyskinesia, Drug-Induced
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day).
- Conditions
- Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
- Trial name
- NCT04857359
- Testing
- Dipraglurant
- Where
- 41 sites in United States
- Volunteers
- 25 people
- Sponsor
- Addex Pharma S.A.
Hepatitis C, Chronic
An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)
This observational study will assess factors leading to dose reductions/treatment discontinuations and the effect on sustained virological response in patients with chronic hepatitis C receiving a long-acting interferon (e.g.
- Trial name
- NCT01344889
- Where
- 260 sites in Albania, Algeria and 23 more
- Volunteers
- 4,459 people
- Sponsor
- Hoffmann-La Roche
Graft vs Host Disease, Congenital Aniridia
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation
The ARGOS-IO pressure sensor is intended to be implanted in the human eye in combination with Boston Keratoprosthesis (BKPro) surgery and to remain in place indefinitely.
- Conditions
- Graft vs Host Disease, Congenital Aniridia, Chemical Burns, Stevens-Johnson Syndrome
- Trial name
- NCT02945176
- Testing
- ARGOS-IO system
- Where
- 2 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Implandata Ophthalmic Products GmbH